Researchers at the RIKEN Research Centre for Allergy and Immunology revealed they have succeeded for the first time in creating cancer-specific, immune system cells called killer T lymphocytes, the Daily Mail said.
To create these, the team first had to reprogramme T lymphocytes specialized in killing a certain type of cancer, into another type of cell called induced pluripotent stem cells (iPS cells). These iPS cells then generated fully active, cancer-specific T lymphocytes. These lymphocytes regenerated from iPS cells could potentially serve as cancer therapy in the future, researchers believe.
Previous research has shown that killer T lymphocytes produced in the lab using conventional methods are inefficient in killing cancer cells mainly because they have a very short life-span, which limits their use as treatment for cancer.
Read the rest of the story: Japan offers hope of treating cancer